While not significant in the FinnGen consortium, the Mendelian randomization analysis in the non-FinnGen GWAS revealed that IL-6R blockage would raise the risk of NAFLD. This evidence concerns the gene IL6R and metabolic dysfunction-associated steatotic liver disease.